Technetium-99m-sestamethoxyisobutylisonitrile scan as a predictor of chemotherapy response in malignant lymphomas compared with P-glycoprotein expression, multidrug resistance-related protein expression and other prognosis factors

British Journal of Haematology

Volumn 113, Issue 2, 2001, Pages 369-374

  Kao, Chia Hung ^a   Tsai, Shih Chuan ^a,f   Wang, Jhi Joung ^b   Ho, Yung Jen ^c   Ho, Shung Tai ^d   Changlai, Sheng Ping ^e  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b SHOW CHWAN MEMORIAL HOSPITAL   (Taiwan)

^c Chi Mei Medical Centre   (Taiwan)

^d JEN AI HOSPITAL   (Taiwan)

^e NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^f Department of Nuclear Medicine   (Taiwan)

Author keywords

Chemotherapy response; Malignant lymphoma; Multidrug resistance related protein expression; P glycoprotein expression; Technetium 99m methoxyisobutylisonitrile

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CHLORMETHINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; GLYCOPROTEIN P; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; MULTIDRUG RESISTANCE PROTEIN; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPHOMA; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TREATMENT OUTCOME;

ADULT; CHI-SQUARE DISTRIBUTION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA; MALE; MIDDLE AGED; P-GLYCOPROTEIN; PREDICTIVE VALUE OF TESTS; PROGNOSIS; STATISTICS, NONPARAMETRIC; TECHNETIUM TC 99M SESTAMIBI; TREATMENT OUTCOME;

EID: 0035006051     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2001.02763.x     Document Type: Article

References (23)

1. Haematological malignancies
2. Effect of mitochondrial and plasma membrane potentials on accumulation of hexakis (2-methoxyisobutylisonitrile) technetium (I) in cultured mouse fibroblast
3. Quantitative reverse transcriptase-polymerase chain reaction measured expression of MDR1 and MRP in primary breast carcinoma
4. Uptake and kinetics of Tc-99m hexakis 2-methoxy isobutyl isonitrile in benign and malignant lesions in the lungs
5. 99mTc-sestamibi is a substrate for P-glycoprotein and the multidrug resistance-associated protein
6. Visualization of multidrug resistance in vivo
7. Histopathology of the non-Hodgkin's lymphomas and Hodgkin's disease
8. Technetium-99m methoxyisobutylisonitrile chest imaging of small cell lung carcinoma. Relationship to patient prognosis and chemotherapy response - A preliminary report
9. Quickly predicting chemotherapy response to paclitaxel-based therapy in non-small cell lung cancer by early technetium-99m methoxyisobutylisonitrile chest single-photon-emission computed tomography
10. Evaluation of therapy response in children with untreated malignant lymphomas using technetium-99m-sestamibi
11. P-glycoprotein expression by technetium-99m-MIBI scintigraphy in hematologic malignancy
12. P-glycoprotien in adult hematologic malignancies
13. Lymphoma
14. Immunohistochemical identification of P-glycoprotein in previously untreated, diffuse large cell in immunoblastic lymphomas
15. Functional retention of Tc-99m MIBI in mediastinal lymphomas as a predictor of chemotherapeutic response demonstrated by consecutive thoracic SPECT imaging
16. Expression of mediated p-glycoprotein multidrug resistance related to Tc-99m MIBI scintimamography results
17. Comparison of the kinetics of active efflux of 99mTc-MIBI in cells with P-glycoprotein-mediated and multidrug-resistance protein-associated multidrug-resistance phenotypes
18. mdr1 mRNA expression by RT-PCR in patients with primary breast cancer submitted to neoadjuvant therapy
19. MDR1 and MRP expression in chronic B-cell lymphoproliferative disorders
20. Principles of chemotherapy for lymphomas
21. Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells
22. Application of SPET using technetium-99m sestamibi in brain turnouts and comparison with expression of the MDR-1 gene: Is it possible to predict the response to chemotherapy in patients with gliomas by means of 99mTc-sestamibi SPET?
23. Expression of the multidrug resistance-associated protein gene in refractory lymphoma: Quantitation by a validated polymerase chain reaction assay